Lactulose

Also known as: Lactulose solution, Lactulose syrup

A prescription osmotic laxative with a conditional chronic-constipation recommendation and formulation-specific sugar cautions.

A watercolor and graphite study of an amber syrup-like pool on a pale ceramic tile.
Editorial illustration

Lactulose is a synthetic sugar used as an osmotic laxative. The 2023 AGA/ACG guideline conditionally suggests it for adults with chronic idiopathic constipation who fail or cannot tolerate OTC therapies, with very-low-certainty evidence. Gas, bloating and diarrhea can limit use, and the exact prescription and formulation matter.1, 4

  • The AGA/ACG recommendation for chronic idiopathic constipation is conditional, and its evidence certainty is very low.1
  • A Japanese dose-finding trial randomized 250 adults to crystalline lactulose or placebo for two weeks.2
  • The cited U.S. solution contains 10 g lactulose per 15 mL, with residual galactose, lactose and other sugars.3

What is Lactulose?

Lactulose reaches the colon largely unchanged and is broken down by bacteria into acids that increase water in the stool. MedlinePlus also describes a separate liver-disease use involving ammonia reduction. The clinical purpose determines how a prescription is managed.3, 4, 2

Where it comes from

Natural sources

  • The medication is a manufactured disaccharide composed of galactose and fructose.

How it's made

Studied products include an oral solution and a crystalline-lactulose jelly preparation.

What it does in products

  • Osmotic laxative in prescription medicines
  • Medication used for ammonia management in specified liver disease

Benefits

Constipation relief has a qualified evidence base

limited evidence

Short-term bowel-frequency findings coexist with uncertainty in chronic-condition guidance.2, 1

In the Japanese trial, 26 and 39 g/day increased spontaneous bowel movements more than placebo at week one. The two-week design limits conclusions about sustained treatment. The U.S. guideline's conditional recommendation reflects very-low-certainty evidence in its eligible chronic idiopathic constipation studies.

Evidence scope and limitations

Adult constipation guidance, a short crystalline-lactulose trial, one U.S. solution label and NLM medication information.

  • The Japanese trial lasted two weeks, used one preparation and included functional constipation without excluding IBS-C. Its scope differs from the U.S. guideline's chronic idiopathic constipation review.
  • The U.S. label's text was revised in September 2020. It was checked as a current listing, with that revision date retained.
  • This guide does not evaluate a full hepatic encephalopathy treatment protocol, pediatric dosing or every oral preparation.

Evidence last checked: 2026-11-14

Side effects & safety

Gas, bloating, nausea or diarrhea (varies)MedlinePlus advises medical advice for severe or persistent symptoms and immediate contact for stomach pain, cramps or vomiting. Excessive diarrhea can cause fluid and electrolyte losses according to the solution label. Its residual sugars also require caution in diabetes.

Safety considerations

  • Tell the prescriber about pregnancy or breastfeeding. The cited label describes limited controlled pregnancy data. Tell the clinical team about lactulose before colon or rectal procedures.
  • MedlinePlus lists antacids, neomycin and other laxatives for review with a clinician or pharmacist before combining them.
  • Not for: People who require a low-galactose diet, according to the cited solution's galactose-related contraindication.
3, 4, 1

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In constipation labels and trials

The cited solution label describes 15–30 mL/day, equivalent to 10–20 g lactulose, for constipation. The Japanese trial tested 13, 26 and 39 g/day in a different preparation for two weeks. These are label and study contexts. Follow the prescription for the exact product and condition.

3, 2, 4

Regulatory status

  • The cited DailyMed record is a U.S. prescription-drug label for oral lactulose solution. It provides product-specific constipation directions and warnings. Broader liver-disease use is described by NLM and requires its own clinical regimen.
3, 4

Why the indication and preparation matter

Lactulose's two familiar medical uses involve different goals. A constipation response concerns stool passage. In liver disease, clinical management can target ammonia-related complications and uses separately prescribed schedules. Carrying directions across those settings could change the treatment substantially.

The 2019 trial used a crystalline preparation in predominantly female Japanese adults and lasted two weeks. Its positive bowel-frequency result supplies a short-term efficacy signal. The guideline's more cautious chronic-condition conclusion retains importance when judging durability and certainty.

4, 2, 1

Frequently asked questions

How quickly does the solution work?

The cited label describes a possible 24–48-hour wait for a bowel movement. A delayed response should be discussed using the prescribed plan, particularly when pain, vomiting or significant diarrhea occurs.3, 4

The bottom line

Read lactulose through the exact prescription, indication and residual-sugar warnings, while keeping chronic-condition evidence uncertainty visible.

References

  1. Chang L, Chey WD, Imdad A, et al.. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. The American Journal of Gastroenterology (2023) · clinical guideline · DOI 10.14309/ajg.0000000000002227; 118(6):936–954; conditional lactulose recommendation and very-low-certainty evidence checked
  2. Kasugai K, Iwai H, Kuboyama N, Yoshikawa A, Fukudo S. Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study. Journal of Gastroenterology (2019) · randomized trial · DOI 10.1007/s00535-018-01545-7; 54:530–540; published January 14, 2019; Japic CTI-132219; original methods, two-week results and adverse reactions checked
  3. Lactulose Solution, USP — prescription label. Chartwell RX, LLC / DailyMed (2020) · ingredient monograph · SPL set ID bd9f1577-65e8-4521-b176-e5fc60a4a018; label text revised September 2020, current listing checked November 14, 2026; 10 g/15 mL constipation formulation
  4. Lactulose. MedlinePlus / U.S. National Library of Medicine (2024) · ingredient monograph · Patient medication information last revised January 15, 2024; current page checked November 14, 2026

Revision history

  1. Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.